Dieter Kabelitz Selected Research

Antigens

1/2022	Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen.
1/2020	Real-time cell analysis (RTCA) to measure killer cell activity against adherent tumor cells in vitro.
1/2017	Immunosurveillance by human γδ T lymphocytes: the emerging role of butyrophilins.
6/2014	The CD3 conformational change in the γδ T cell receptor is not triggered by antigens but can be enforced to enhance tumor killing.
3/2014	Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.
1/2014	Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy.
6/2013	Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration.
6/2011	High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia.
7/2008	2-D DIGE analyses of enriched secretory lysosomes reveal heterogeneous profiles of functionally relevant proteins in leukemic and activated human NK cells.
6/2006	Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dieter Kabelitz Research Topics

Disease

59	Neoplasms (Cancer) 01/2022 - 01/2002
10	Infections 01/2022 - 01/2003
9	Adenocarcinoma 01/2020 - 12/2004
8	Inflammation (Inflammations) 01/2020 - 01/2003
7	Necrosis 02/2014 - 06/2002
6	Lymphoma (Lymphomas) 01/2021 - 06/2003
4	Leukemia 01/2019 - 12/2003
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019 - 09/2007
4	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 06/2011 - 12/2003
3	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2011
3	Multiple Myeloma 09/2017 - 06/2006
3	Hypersensitivity (Allergy) 11/2016 - 08/2010
3	Infertility (Sterility) 05/2016 - 09/2006
3	Neoplasm Metastasis (Metastasis) 03/2015 - 02/2008
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2006 - 06/2003
3	Hematologic Neoplasms (Hematological Malignancy) 06/2006 - 06/2003
2	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 01/2017
2	Carcinoma (Carcinomatosis) 01/2019 - 10/2013
2	Melanoma (Melanoma, Malignant) 01/2019 - 12/2004
2	Glioma (Gliomas) 03/2018 - 04/2016
2	Carcinogenesis 01/2017 - 03/2015
2	Osteonecrosis (Kienbock's Disease) 07/2015 - 06/2014
2	Macular Degeneration (Age-Related Maculopathy) 02/2015 - 12/2009
2	Osteoporosis 04/2014 - 06/2010
2	Autoimmune Diseases (Autoimmune Disease) 02/2008 - 04/2006
1	COVID-19 01/2022
1	Bites and Stings (Sting) 01/2022
1	Hepatitis B 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Liver Neoplasms (Liver Cancer) 01/2021
1	HIV Infections (HIV Infection) 05/2020
1	Type 2 Diabetes Mellitus (MODY) 02/2020

Drug/Important Bio-Agent (IBA)

13	LigandsIBA 01/2022 - 08/2005
12	AntigensIBA 01/2022 - 12/2003
10	CytokinesIBA 01/2022 - 01/2005
10	Proteins (Proteins, Gene)FDA Link 01/2019 - 06/2003
7	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2017 - 01/2007
5	Biological ProductsIBA 01/2022 - 05/2006
5	NK Cell Lectin-Like Receptor Subfamily KIBA 01/2022 - 04/2016
5	Diphosphates (Pyrophosphates)IBA 01/2021 - 06/2010
5	Bispecific AntibodiesIBA 01/2020 - 01/2014
4	Peptides (Polypeptides)IBA 01/2017 - 06/2003
4	CaspasesIBA 10/2013 - 06/2002
4	Laminin ReceptorsIBA 06/2011 - 12/2003
3	AntibodiesIBA 01/2022 - 08/2010
3	Carrier Proteins (Binding Protein)IBA 01/2022 - 04/2016
3	ChemokinesIBA 01/2022 - 01/2003
3	InterferonsIBA 01/2022 - 01/2019
3	RNA (Ribonucleic Acid)IBA 01/2021 - 06/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2020 - 06/2002
3	Monoclonal AntibodiesIBA 01/2019 - 07/2009
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 12/2009
3	micaIBA 01/2019 - 10/2013
3	diphosphoric acid (pyrophosphoric acid)IBA 01/2017 - 01/2010
3	Metalloproteases (Metalloproteinases)IBA 04/2016 - 10/2013
3	DisintegrinsIBA 04/2016 - 10/2013
3	Diphosphonates (Bisphosphonates)IBA 07/2015 - 06/2014
3	NitrogenIBA 07/2015 - 06/2014
3	Death Domain ReceptorsIBA 09/2014 - 06/2002
3	CeramidesIBA 02/2014 - 01/2011
3	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 01/2011 - 07/2007
2	VaccinesIBA 01/2022 - 02/2008
2	Zoledronic Acid (Zometa)FDA Link 01/2022 - 06/2014
2	Immunoglobulin G (IgG)IBA 01/2022 - 06/2015
2	human ERBB2 proteinIBA 01/2022 - 01/2018
2	AntioxidantsIBA 01/2021 - 04/2014
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2020 - 11/2009
2	ErbB Receptors (EGF Receptor)IBA 01/2020 - 11/2016
2	Insulin (Novolin)FDA Link 01/2020 - 02/2008
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2020 - 03/2014
2	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 01/2019 - 02/2014
2	Pattern Recognition ReceptorsIBA 01/2019 - 01/2008
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 05/2006
2	TNF-Related Apoptosis-Inducing LigandIBA 01/2019 - 11/2006
2	Granzymes (Granzyme)IBA 01/2019 - 11/2009
2	Trastuzumab (Herceptin)FDA Link 01/2018 - 11/2016
2	Surface Antigens (Surface Antigen)IBA 01/2018 - 03/2013
2	Interleukin-17 (Interleukin 17)IBA 01/2017 - 03/2014
2	Pharmaceutical PreparationsIBA 07/2015 - 06/2014
2	Phosphotransferases (Kinase)IBA 02/2014 - 01/2011
2	Interleukin-2 (IL2)IBA 06/2010 - 12/2004
1	citrate-binding transport proteinIBA 01/2022
1	PhycoerythrinIBA 01/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	ORALIT (ORS)IBA 09/2021
1	Oxidants (Oxidizing Agents)IBA 01/2021
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 01/2021
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 11/2020
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 11/2020
1	Galectins (Galectin)IBA 11/2020
1	CreatinineIBA 05/2020
1	Urea (Carbamide)FDA LinkGeneric 05/2020
1	Chemotactic FactorsIBA 02/2020
1	IncretinsIBA 02/2020
1	Dipeptidyl-Peptidase IV InhibitorsIBA 02/2020
1	Blood Glucose (Blood Sugar)IBA 02/2020
1	Glucose (Dextrose)FDA LinkGeneric 02/2020
1	Galectin 3 (LGALS3)IBA 01/2020

Therapy/Procedure

32	Immunotherapy 01/2022 - 12/2004
16	Therapeutics 01/2022 - 01/2002